Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1909 in advanced malignant tumors
NCT05162469Phase 1Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Feb 2022
- Primary completion
- Mar 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SHR-1909 in cancer, sponsored by Hengrui Therapeutics. Primary endpoints: Maximum Tolerated Dose at 4 weeks and Recommended Phase 2 Dose at 90 days. Started Feb 2022; status: completed.
02
Drugs
SHR-1909
03
Conditions
cancer
Beyond the preview
Go deeper on NCT05162469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05162469.